📣 VC round data is live. Check it out!

Star Lake Bioscience Valuation Multiples

Discover revenue and EBITDA valuation multiples for Star Lake Bioscience and similar public comparables like MBX Biosciences, KalVista Pharmaceuticals, GH Research, Bicara Therapeutics and more.

Star Lake Bioscience Overview

About Star Lake Bioscience

Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.


Founded

1992

HQ

China

Employees

2.7K

Financials (LTM)

Revenue: $2B
EBITDA: $314M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Star Lake Bioscience Financials

Star Lake Bioscience reported last 12-month revenue of $2B and EBITDA of $314M.

In the same LTM period, Star Lake Bioscience generated $389M in gross profit, $314M in EBITDA, and $147M in net income.

Revenue (LTM)


Star Lake Bioscience P&L

In the most recent fiscal year, Star Lake Bioscience reported revenue of $2B and EBITDA of $315M.

Star Lake Bioscience is profitable as of last fiscal year, with gross margin of 17%, EBITDA margin of 14%, and net margin of 6%.

See analyst estimates for Star Lake Bioscience
LTMLast FY202320242025202620272028
Revenue$2B$2B$3B$3B$2B
Gross Profit$389M$385M$357M$436M$385M
Gross Margin17%17%14%17%17%
EBITDA$314M$315M$277M$321M$315M
EBITDA Margin13%14%11%13%14%
EBIT Margin8%8%7%9%8%
Net Profit$147M$143M$99M$138M$143M
Net Margin6%6%4%5%6%
Net Debt—$453M———

Financial data powered by Morningstar, Inc.

Star Lake Bioscience Stock Performance

Star Lake Bioscience has current market cap of $1B, and enterprise value of $2B.

Market Cap Evolution


Star Lake Bioscience's stock price is $0.85.

Star Lake Bioscience share price increased by 0.1% in the last 30 days, and decreased by 21.1% in the last year.

Star Lake Bioscience has an EPS (earnings per share) of $0.09.

See more trading valuation data for Star Lake Bioscience
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$1B0.0%0.1%-24.3%-21.1%$0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Star Lake Bioscience Valuation Multiples

Star Lake Bioscience trades at 0.9x EV/Revenue multiple, and 6.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Star Lake Bioscience

EV / Revenue (LTM)


Star Lake Bioscience Financial Valuation Multiples

As of May 4, 2026, Star Lake Bioscience has market cap of $1B and EV of $2B.

Star Lake Bioscience has a P/E ratio of 9.6x.

LTMLast FY202320242025202620272028
EV/Revenue0.9x0.9x0.8x0.8x0.9x
EV/EBITDA6.9x6.8x7.8x6.7x6.8x
EV/EBIT11.7x11.4x11.9x9.0x11.4x
EV/Gross Profit5.5x5.6x6.0x4.9x5.6x
P/E9.6x9.9x14.3x10.3x9.9x
EV/FCF—(19.7x)8.9x8.3x(19.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Star Lake Bioscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Star Lake Bioscience Margins & Growth Rates

Star Lake Bioscience grew revenue by 4% and EBITDA by 5% in the last fiscal year.

In the most recent fiscal year, Star Lake Bioscience reported gross margin of 17%, EBITDA margin of 14%, and net margin of 6%.

See estimated margins and future growth rates for Star Lake Bioscience

Star Lake Bioscience Margins

Last FY202420252026202720282029
Gross Margin17%17%17%17%
EBITDA Margin14%13%14%14%
EBIT Margin8%9%8%8%
Net Margin6%5%6%6%
FCF Margin(5%)10%(5%)—

Star Lake Bioscience Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth4%(0%)(8%)4%
Gross Profit Growth5%22%(12%)5%
EBITDA Growth5%16%(2%)5%
EBIT Growth7%32%(21%)7%
Net Profit Growth9%39%4%9%
FCF Growth—7%(142%)—

Data powered by FactSet, Inc. and Morningstar, Inc.

Star Lake Bioscience Operational KPIs

Star Lake Bioscience's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.1M for the same period.

Star Lake Bioscience's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Star Lake Bioscience's Rule of X is 24% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Star Lake Bioscience
LTMLast FY202320242025202620272028
Rule of 4019%18%———
Bessemer Rule of X27%24%———
Revenue per Employee—$0.9M———
Opex per Employee—$0.1M———
S&M Expenses to Revenue—1%1%1%1%
G&A Expenses to Revenue5%5%1%1%1%
R&D Expenses to Revenue—1%1%1%1%
Opex to Revenue—8%7%8%8%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Star Lake Bioscience Competitors

Star Lake Bioscience competitors include MBX Biosciences, KalVista Pharmaceuticals, GH Research, Bicara Therapeutics, WAVE Life Sciences, Liaoning Chengda Biotech, Immunocore Holdings, ArriVent BioPharma, HBM Holdings and Immatics.

Most Star Lake Bioscience public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
MBX Biosciences——(10.7x)(9.0x)
KalVista Pharmaceuticals25.8x12.3x(7.3x)—
GH Research——(23.8x)(16.6x)
Bicara Therapeutics——(6.8x)(6.3x)
WAVE Life Sciences20.6x18.4x(4.3x)(4.2x)
Liaoning Chengda Biotech3.2x3.2x12.6x14.2x
Immunocore Holdings2.5x2.4x(273.7x)(24.5x)
ArriVent BioPharma——(6.1x)(6.0x)

This data is available for Pro users. Sign up to see all Star Lake Bioscience competitors and their valuation data.

Start Free Trial

Star Lake Bioscience M&A Activity

Star Lake Bioscience has acquired 1 company to date.

Last acquisition by Star Lake Bioscience was on April 2nd 2022. Star Lake Bioscience acquired Ningxia Yipin for $759M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Star Lake Bioscience

Ningxia Yipin
Description
Ningxia Yipin is a bio-fermentation technology company based in Ningxia, China, specializing in the production of L-lysine and other amino acids. Operating under Eppen brand, it supplies feed-grade additives to global livestock industries. The firm maintains production facilities in Shizuishan and holds certifications for high-purity fermentation processes.
HQ CountryChina
HQ City
Yinchuan
Deal Date2 Apr 2022
Valuation$759M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Star Lake Bioscience acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Star Lake Bioscience

When was Star Lake Bioscience founded?Star Lake Bioscience was founded in 1992.
Where is Star Lake Bioscience headquartered?Star Lake Bioscience is headquartered in China.
How many employees does Star Lake Bioscience have?As of today, Star Lake Bioscience has over 2K employees.
Is Star Lake Bioscience publicly listed?Yes, Star Lake Bioscience is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Star Lake Bioscience?Star Lake Bioscience trades under 600866 ticker.
When did Star Lake Bioscience go public?Star Lake Bioscience went public in 1994.
Who are competitors of Star Lake Bioscience?Star Lake Bioscience main competitors include MBX Biosciences, KalVista Pharmaceuticals, GH Research, Bicara Therapeutics, WAVE Life Sciences, Liaoning Chengda Biotech, Immunocore Holdings, ArriVent BioPharma, HBM Holdings, Immatics.
What is the current market cap of Star Lake Bioscience?Star Lake Bioscience's current market cap is $1B.
What is the current revenue of Star Lake Bioscience?Star Lake Bioscience's last 12 months revenue is $2B.
What is the current revenue growth of Star Lake Bioscience?Star Lake Bioscience revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Star Lake Bioscience?Current revenue multiple of Star Lake Bioscience is 0.9x.
Is Star Lake Bioscience profitable?Yes, Star Lake Bioscience is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Star Lake Bioscience?Star Lake Bioscience's last 12 months EBITDA is $314M.
What is Star Lake Bioscience's EBITDA margin?Star Lake Bioscience's last 12 months EBITDA margin is 13%.
What is the current EV/EBITDA multiple of Star Lake Bioscience?Current EBITDA multiple of Star Lake Bioscience is 6.9x.
How many companies Star Lake Bioscience has acquired to date?As of May 2026, Star Lake Bioscience has acquired 1 company.
What was the largest acquisition by Star Lake Bioscience?$759M acquisition of Ningxia Yipin on 2nd April 2022 was the largest M&A Star Lake Bioscience has done to date.
What companies Star Lake Bioscience acquired?Star Lake Bioscience acquired Ningxia Yipin.
In how many companies Star Lake Bioscience has invested to date?Star Lake Bioscience hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Star Lake Bioscience

Lists including Star Lake Bioscience

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial